Monascus
Download
1 / 1

Abstract - PowerPoint PPT Presentation


  • 148 Views
  • Uploaded on

Monascus rice powder co-supplemented with coenzyme Q 10 improves serum lipids and LDL-lag time on hypercholesterolemia subjects. Shih-Wen Hsu 1# , Yi-Ting Lin 1 , Hui-Ting Yang 2 , Ching-Chien Chang 1 , Ming-Jer Shieh 1 , and Shih-Yi Huang 1 *

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Abstract' - loren


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Monascus rice powder co-supplemented with coenzyme Q10 improves serum lipids and LDL-lag time on hypercholesterolemia subjects.

Shih-Wen Hsu1#, Yi-Ting Lin1, Hui-Ting Yang2, Ching-Chien Chang1, Ming-Jer Shieh1, and Shih-Yi Huang1*

1School of Nutrition and Health Sciences,Taipei Medical University,Taipei, Taiwan.

2 Department of Medical Nutrition, I-Shou University, Kaohsiung, Taiwan.

ab

ab

bb

bb

(A)

(C)

240

a

a

ac

a

c

a

150

150

aa

b

b

b

b

**

160

**

100

100

MQ

LDL level (mg/dL)

Lagtime (min)

HMQ

a a a

*

80

b

M

MQ

50

50

a ab b ab

b

MHQ

M

0

0

0

Time (week)

-2

0

3

6

8

Time (week)

0

3

6

8

(B)

(D)

)

a

a

a

a

a

a

300

120

dL

b

c

b

b

200

80

a a

a

HDL level (mg/dL)

MQ

Cholesterol level (mg/

b

100

40

b

HMQ

MQ

M

HMQ

0

M

Time (week)

-2

0

3

6

8

0

Time (week)

-2

0

3

6

8

Abstract

Recent studies showed a possibly interruption of monacolins, byproducts of Monascus rice powder, on coenzyme Q10 biosynthesis. Thus, a clinical trial was conducted to investigate lipid-lowering and antioxidative effects of combined red yeast rice extract and coenzyme Q10 (CoQ10) supplementation on hypercholesterolemia subjects. 37 subjects were recruited and were randomly divided into three groups such as Monascus rice powder 250 mg (M), equivalent to monacolins 6 mg; Monascus rice powder 250 mg plus CoQ10 15 mg (MQ), and Monascus rice powder 500 mg plus CoQ10 30 mg (HMQ) by different doses supplementation. The supplementations administrated for 6 weeks, blood samples were collected every two weeks for cholesterol and low density lipoprotein (LDL) lag time determination. Results showed that all of the groups had lower serum total cholesterol (19.6%, 32.7%, and 19.6% decrease from baseline, p<0.05) and LDL cholesterol concentration (28.6%, 42.3%, and 29.0% decrease from baseline, p<0.05) after three weeks of supplementation. Moreover, there were no alterations on high density lipoprotein (HDL) cholesterol level of all subjects. In LDL-lag time, the data displayed a significant slower production of conjugated dienes in all groups after six weeks of supplementation. However, in CoQ10 supplementing groups, the effect sustained after ceasing supplementation for two weeks. The results reconfirmed the lipid-lowering effects of monacolins and 250 mg Monascus rice powder, (equivalent to monacolins 6 mg) supplementation didn’t affect the LDL oxidative process through disruption of CoQ10 metabolism. Furthermore, addition of at least 15 mg CoQ10 could significantly enhance LDL antioxidative capacity in hypercholesterolemia subjects.

Subjects and Methods

37 subjects were recruited and were randomly divided into three groups such as Monascus rice powder 250 mg (M), equivalent to monacolins 10 mg; Monascus rice powder 250 mg plus CoQ10 15 mg (MQ), and Monascus rice powder 500 mg plus CoQ10 30 mg (HMQ) by different doses supplementation. The supplementations administrated for 6 weeks, blood samples were collected every two weeks for cholesterol and low density lipoprotein (LDL) lag time determination. The final results were presented as mean ± SD. Student’s t test was used for statistically analysis.

Results

Fig. (A) LDL lag time of different groups,

Fig. (B) Cholesterol concentrations of different groups,

Fig. (C) LDL concentrations of different groups,

Fig. (D) HDL concentrations of different groups,

"a, b, c“represented significant differences with different time periods;”*,**” represented significant differences within groups, p<0.05.

Discussion

Recent studies showed the active compound of Monascus rice powder, Monacolin K, could inhibit hydroxymethyl glutaryl coA reductase (HMG CoA reductase) which are the key enzyme of internal cholesterol synthesis in our body. The present results showed that daily intake of 250mg Monascus rice powder (equivalent to 6mg of monacolins) significantly lowered serum total and LDL cholesterol concentration ( p<0.05) and remained normal after three weeks of supplementation. Besides, there were no alterations on high density lipoprotein (HDL) cholesterol level of all subjects.

In LDL-lag time, the data displayed a significant delayed production of conjugated dienes in all groups after six weeks of Monascus rice powder supplementation. However, in CoQ10 supplementing groups, the effect sustained after empty intervention for two weeks. The results reconfirmed the lipid-lowering effects of Monascus rice powder and the supplementation didn’t accelerate LDL oxidation through disruption of CoQ10 metabolism. Furthermore, addition of at least 15 mg CoQ10 could significantly enhance LDL antioxidative capacity in hypercholesterolemia subjects.

Conclusion

Daily supplemented with 250 mg of Monascus rice powder and 15 mg of CoQ10 for six weeks could not only significantly regulate serum total and LDL cholesterol concentration in subjects with hypercholesterolemia but also delayed LDL oxidation. The combination might assist to decrease the risk of atherosclerosis progress and to prevent the incidence of cardiovascular disease.


ad